C. Snowdon

发表

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen

J. Jassem, R. C. Coombes, G. Bertelli, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

J. Cuzick, J. Forbes, R. Peto, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

H. Gevensleben, D. Rea, J. Braybrooke, 2020, The Lancet. Oncology.

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

R. Coombes, L. Fallowfield, R. C. Coombes, 2012, British Journal of Cancer.

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

S. Cawthorn, R. C. Coombes, E. Hall, 2007, The Lancet. Oncology.

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer

N. Turner, A. Ring, L. Kilburn, 2022, Trials.

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

M. Sydes, C. Yap, M. Copland, 2022, Trials.

Conducting non-commercial international clinical trials: the ICR-CTSU experience

J. Bliss, C. Snowdon, Lisa Fox, 2017, Trials.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

I. Judson, B. Seddon, M. Tattersall, 2019, The Lancet. Oncology.

Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study

P. Lønning, L. Fallowfield, L. Gibson, 2003, BMJ : British Medical Journal.

First mature analysis of the Intergroup Exemestane Study.

R. Paridaens, T. Delozier, C. V. D. van de Velde, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5010 Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) – submitted on behalf of the IES Investigators

J. Bliss, C. Snowdon, L. Kilburn, 2009 .

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

R. Coombes, L. Fallowfield, E. Hall, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

D. Rea, J. Braybrooke, D. Cameron, 2020 .

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.

T. Hickish, M. Hubank, A. Wardley, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

M. Wilcox, I. Bhattacharya, J. Haviland, 2018, Research Involvement and Engagement.

Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118).

I. Judson, B. Seddon, J. Bliss, 2017 .

Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

A. Wardley, R. Roylance, N. Turner, 2018 .

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

A vision for inclusive and transparent health data in the beyond. Learning

M. Tattersall, I. Judson, B. Seddon, 2019 .

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

R. Paridaens, M. Carpentieri, C. Snowdon, 2004, The New England journal of medicine.

Does it matter if clinicians recruiting for a trial don't understand what the trial is really about? Qualitative study of surgeons' experiences of participation in a pragmatic multi-centre RCT

Claire Snowdon, Marion K Campbell, Jonathan A Cook, 2007, Trials.